Steminent Biotherapeutics Inc. (TPEX:7729)

Steminent Biotherapeutics Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021	Dec 31, 2020
Net Income	-155.75	-158.75	-129.23	-124.2	-55.21
Depreciation & Amortization	24.1	16.43	12.06	11.33	15.38
Loss (Gain) From Sale of Assets	-	-	-	-0	0.01
Loss (Gain) From Sale of Investments	-	-	-	0.46	-
Stock-Based Compensation	8.65	15.88	8.58	0.63	0.54
Other Operating Activities	0.47	0.05	-0.64	53.32	10.33
Change in Accounts Receivable	-	-	0.1	-0.55	0.34
Change in Inventory	3.25	-4.33	-4.19	0.2	2.33
Change in Accounts Payable	0.57	0.39	0.23	-0.21	-3.3
Change in Unearned Revenue	-	-	-0.46	1.02	0.08
Change in Other Net Operating Assets	-9.58	-9.1	-1.25	2.9	-1.96
Operating Cash Flow	-128.29	-139.41	-114.81	-55.11	-31.47
Capital Expenditures	-42.97	-87.15	-27.46	-0.6	-
Sale of Property, Plant & Equipment	-	-	-	0	-
Sale (Purchase) of Intangibles	-0.75	-1.22	-0.25	-	-
Investment in Securities	-32.02	-11.6	-	-	-
Other Investing Activities	-	-	-0.84	0.05	-0.01
Investing Cash Flow	-75.74	-99.97	-28.56	-0.55	-0.01
Long-Term Debt Repaid	-	-11.64	-6.84	-7.64	-7.35
Net Debt Issued (Repaid)	13.78	-11.64	-6.84	-7.64	-7.35
Issuance of Common Stock	5.3	4.15	450.26	251.6	-
Other Financing Activities	-	-	-1.46	1.46	-
Financing Cash Flow	19.08	-7.49	441.95	245.42	57.82
Foreign Exchange Rate Adjustments	-0.61	0.42	-0.16	-0.02	-0.1
Net Cash Flow	-185.57	-246.46	298.43	189.75	26.24
Free Cash Flow	-171.27	-226.57	-142.27	-55.71	-31.47
Free Cash Flow Margin	-	-	-15119.02%	-2626.69%	-61.14%
Free Cash Flow Per Share	-3.05	-4.05	-2.94	-1.58	-1.05
Cash Interest Paid	1.98	1.92	1.78	1.33	0.79
Cash Income Tax Paid	0.06	0.36	0.25	-0.07	3.67
Levered Free Cash Flow	-	-170.31	-	-32.43	-
Unlevered Free Cash Flow	-	-169.12	-	-31.6	-
Change in Working Capital	-5.76	-13.03	-5.58	3.36	-2.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.